Windtree Therapeutics announces presentation highlighting istaroxime

Windtree Therapeutics (WINT) announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a presentation highlighting the data on istaroxime from the recently completed Phase 2b SEISMiC B study in early cardiogenic shock due to heart failure. The presentation was given at the Cardiovascular Clinical Trials Conference in Washington, DC. Dr. Alexandre Mebazaa is Professor of Medicine at Universite Paris Cite, Chair of Department of Anesthesia & Critical Care and an expert in heart failure and cardiogenic shock. He is part of the task force that wrote the 2021 ESC/HFA Guidelines of Heart Failure and the 2023 addendum. Early cardiogenic shock is characterized by low blood pressure, leaving the patient at risk of developing inadequate blood flow to vital organs leading to high morbidity and mortality. Istaroxime is a novel first-in-class investigational therapy that is intended to improve cardiac function and increase blood pressure to reverse the condition. Istaroxime maintains renal function and has a generally favorable safety profile. Istaroxime has been studied in four positive Phase 2 trials enrolling patients with acute heart failure and early cardiogenic shock due to heart failure.